Drug intelligence / Profile preview

CPG1

Development stage: Preclinical
Modality: Small Molecules
Administration: Topical

Overview

CPG1 is a metallogelator derived from coordination polymers, synthesized from a nitrile-functionalized terpyridyl ligand, various dicarboxylic acids, and transition metal salts. It has demonstrated anticancer activity against the melanoma cell line B16-F10, while being noncytotoxic to noncancerous cells. CPG1 inhibits cell migration, induces apoptosis with cell cycle arrest in the G0/G1 phase, and targets side population cells, which are known to reduce metastasis. It also prevents the growth of tumor spheroids. It is being developed as a topical gel for treating skin cancer.

Other names: metallogelator CPG1

Beyond the preview

Go deeper on CPG1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CPG1.

Explore the full profile